Saba Capital Management, L.P. Arbutus Biopharma Corp Transaction History
Saba Capital Management, L.P.
- $4.06 Billion
- Q4 2024
A detailed history of Saba Capital Management, L.P. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Saba Capital Management, L.P. holds 887,993 shares of ABUS stock, worth $3.06 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
887,993
Previous 676,427
31.28%
Holding current value
$3.06 Million
Previous $2.6 Million
11.48%
% of portfolio
0.07%
Previous 0.06%
Shares
4 transactions
Others Institutions Holding ABUS
# of Institutions
165Shares Held
102MCall Options Held
649KPut Options Held
666K-
Morgan Stanley New York, NY22.6MShares$77.9 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.2MShares$45.7 Million22.74% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$39.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.98MShares$31 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.74MShares$30.2 Million4.68% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $517M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...